5.71 USD
▲+0.10+1.24%
盘后 5.57 -1.24%
2026-08-03
市值
$64.40M
市盈率
—
EPS
-7.06
股息率
—
52 周区间
3.94 – 17.50
成交量
7.23K
Beta
—
目标价
13.00
52W 低 3.9452W 高 17.50
价格走势
公司简介
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.